Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis
暂无分享,去创建一个
[1] M. Perazella,et al. Dabigatran and kidney disease: a bad combination. , 2013, Clinical journal of the American Society of Nephrology : CJASN.
[2] R. Thadhani,et al. No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease. , 2013, Kidney international.
[3] T. Slowinski,et al. Effective elimination of dabigatran by haemodialysis , 2013, Thrombosis and Haemostasis.
[4] R. Stafford,et al. National Trends in Oral Anticoagulant Use in the United States, 2007 to 2011 , 2012, Circulation. Cardiovascular quality and outcomes.
[5] Gordon H Guyatt,et al. Executive Summary Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 2012 .
[6] Gordon H Guyatt,et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[7] M. Eliasziw,et al. New options in anticoagulation for atrial fibrillation. , 2011, The New England journal of medicine.
[8] H. Bruck,et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. , 2010, British journal of clinical pharmacology.
[9] H. Masumoto,et al. Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers , 2010, Journal of clinical pharmacology.
[10] B. Gage. Can we rely on RE-LY? , 2009, The New England journal of medicine.
[11] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[12] R. Thadhani,et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. , 2009, Journal of the American Society of Nephrology : JASN.
[13] H. Nar,et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. , 2002, Journal of medicinal chemistry.
[14] M. Rich,et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. , 2001, JAMA.
[15] R. Beyth,et al. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. , 1998, The American journal of medicine.
[16] R. Troughton,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.